Researchers engineer CAR-astrocytes to target and remove amyloid plaques in Alzheimer’s, showing a 50% reduction in brain ...

As a world leader in the immuno-oncology field, Dr. Zihai Li has long been at the forefront of cancer immunotherapy.

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies. However, nearly half of patients show limited ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...

Clinicians must consider patient comorbidities and therapy safety when selecting immunotherapy for cSCC, says Todd ...

A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.

IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.

Breakthrough immunotherapy trials are showing unprecedented responses in a subset of rectal cancer patients, hinting at a ...

A naturally occurring byproduct of liver metabolism—the ketone body, β-hydroxybutyrate (BHB)—can strengthen the fitness and antitumor activity of CAR T cells. The findings, reported on March 6, 2026 ...

Fecal microbiota transplants may enhance patients’ response to immunotherapy, but experts caution that the latest data remain proof-of-concept and far from practice-changing.

Children with food allergy who used omalizumab plus oral immunotherapy vs. omalizumab alone had similar rates of allergen ...